ELICIO THERAPEUTICS INC (ELTX) Stock Price, Forecast & Analysis
USA - NASDAQ:ELTX - US28657F1030 - Common Stock
ELTX Key Statistics, Chart & Performance
The current stock price of ELTX is 9.29 USD. In the past month the price decreased by -15.85%. In the past year, price increased by 102.4%.
ELTX Latest News, Press Relases and Analysis
ELTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About ELTX
Company Profile
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Company Info
ELICIO THERAPEUTICS INC
451 D Street, 5Th Floor
Boston MASSACHUSETTS US
Employees: 32
Phone: 18572090050
ELICIO THERAPEUTICS INC / ELTX FAQ
Can you describe the business of ELICIO THERAPEUTICS INC?
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
What is the current price of ELTX stock?
The current stock price of ELTX is 9.29 USD. The price increased by 0.43% in the last trading session.
What is the dividend status of ELICIO THERAPEUTICS INC?
ELTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ELTX stock?
ELTX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about ELICIO THERAPEUTICS INC (ELTX) stock?
8 analysts have analysed ELTX and the average price target is 15.81 USD. This implies a price increase of 70.18% is expected in the next year compared to the current price of 9.29.
Can you provide the sector and industry classification for ELICIO THERAPEUTICS INC?
ELICIO THERAPEUTICS INC (ELTX) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ELTX stock?
ELICIO THERAPEUTICS INC (ELTX) has a market capitalization of 151.80M USD. This makes ELTX a Micro Cap stock.
ELTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ELTX. When comparing the yearly performance of all stocks, ELTX is one of the better performing stocks in the market, outperforming 90.63% of all stocks.
ELTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ELTX. ELTX has a bad profitability rating. Also its financial health evaluation is rather negative.
ELTX Financial Highlights
Over the last trailing twelve months ELTX reported a non-GAAP Earnings per Share(EPS) of -3.94. The EPS increased by 18.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -184.95% | ||
| ROE | -2977.75% | ||
| Debt/Equity | 5.09 |
ELTX Forecast & Estimates
8 analysts have analysed ELTX and the average price target is 15.81 USD. This implies a price increase of 70.18% is expected in the next year compared to the current price of 9.29.